Biosyent Inc banner

Biosyent Inc
XTSX:RX

Watchlist Manager
Biosyent Inc Logo
Biosyent Inc
XTSX:RX
Watchlist
Price: 14.97 CAD 3.24% Market Closed
Market Cap: CA$171.9m

Biosyent Inc
Inventory

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Biosyent Inc
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Biosyent Inc
XTSX:RX
Inventory
CA$5.9m
CAGR 3-Years
12%
CAGR 5-Years
36%
CAGR 10-Years
13%
Bausch Health Companies Inc
TSX:BHC
Inventory
$1.6B
CAGR 3-Years
15%
CAGR 5-Years
5%
CAGR 10-Years
3%
Canopy Growth Corp
TSX:WEED
Inventory
CA$105.6m
CAGR 3-Years
-21%
CAGR 5-Years
-23%
CAGR 10-Years
15%
Cronos Group Inc
TSX:CRON
Inventory
$48.2m
CAGR 3-Years
12%
CAGR 5-Years
-3%
CAGR 10-Years
N/A
Mind Medicine (MindMed) Inc
NASDAQ:MNMD
Inventory
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
K
Knight Therapeutics Inc
TSX:GUD
Inventory
CA$144.4m
CAGR 3-Years
19%
CAGR 5-Years
18%
CAGR 10-Years
57%
No Stocks Found

Biosyent Inc
Glance View

Market Cap
171.9m CAD
Industry
Pharmaceuticals

BioSyent, Inc. is a specialty pharmaceutical company, which engages in the development of pharmaceutical and healthcare products. The company is headquartered in Mississauga, Ontario. BioSyent, through its wholly owned subsidiaries BioSyent Pharma Inc. (BioSyent Pharma) and BioSyent Pharma International Inc., acquires or licenses and develops pharmaceutical and other healthcare products for sale in Canada and certain international markets. Hedley Technologies Ltd., a wholly owned subsidiary of BioSyent, operates in the non-chemical insecticide business. BioSyent products include Combogesic, Aguettant System, Cathejell, Cysview, FeraMAX 150, FeraMAX Powder, Proktis-M, RepaGyn, and TIBELLA. Combogesic is for the short-term management of mild to moderate acute pain and the reduction of fever in adults. Aguettant System are used for a variety of injectable medications in hospitals and the acute care setting. FeraMAX 150 is an oral hematinic indicated for the prevention and treatment of iron deficiency anemia. RepaGyn for the healing of the vaginal mucosa and the treatment of vaginal dryness.

RX Intrinsic Value
12.42 CAD
Overvaluation 17%
Intrinsic Value
Price

See Also

What is Biosyent Inc's Inventory?
Inventory
5.9m CAD

Based on the financial report for Sep 30, 2025, Biosyent Inc's Inventory amounts to 5.9m CAD.

What is Biosyent Inc's Inventory growth rate?
Inventory CAGR 10Y
13%

Over the last year, the Inventory growth was 4%. The average annual Inventory growth rates for Biosyent Inc have been 12% over the past three years , 36% over the past five years , and 13% over the past ten years .

Back to Top